Teva Invalidates Opiant Patents In Narcan Suit

Law360 (June 5, 2020, 10:43 PM EDT) -- A New Jersey federal judge found that claims from four patents related to Narcan, the nasal spray treatment for opioid overdoses, are invalid Friday, handing a win to Teva Pharmaceuticals USA Inc. in a suit from the treatment's licensor and licensee Opiant Pharmaceuticals Inc. and Adapt Pharma Operations Ltd.

While the opinion was sealed, an order from U.S. District Judge Brian R. Martinotti indicated that he invalidated claims from U.S. Patent Nos. 9,468,747, 9,561,177, 9,629,965, and 9,775,838 following a two-week bench trial beginning on Aug. 26 and concluding on Sept. 6, with experts testifying in October and closing arguments in February....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!